Selective and non-selective loss of immunoregulatory molecules (HLA-A,B,C antigens and LFA-3) in transitional cell carcinoma. by Nouri, A. M. et al.
Br. J. Cancer (1990), 62, 603-606 1990
Selective and non-selective loss ofimmunoregulatory molecules
(HLA-A,B,C antigens and LFA-3) in transitional cell carcinoma
A.M.E. Nouri, M.E.F. Smith', D. Crosby & R.T.D. Oliver
Medical Oncology, The London Hospital, Whitechapel, London El 2BB, UK; and 'Director's Laboratory, Imperial Cancer
Research Fund, Lincoln's Inn Fields, London WC2, UK.
Summary The expression of the major histocompatibility complex (MHC) class I and II antigens and
lymphocyte function-associated antigen-3 (LFA-3) was investigated using immunohistochemical staining of
bladder tissue sections from 18 patients with transitional cell carcinoma (TCC) and two normal bladder
specimens. The expressions of HLA-A,B,C antigens varied greatly between different tumours. Complete loss
was observed in one of 18 cases. Moderate to strong expression of HLA-A,B,C antigens was observed in 10 of
18 cases with the remaining seven cases showing either weak expression or expression on only a proportion of
the tumour cells. Selective loss of HLA-Bw6 was seen in one of 18 cases. In many cases heterogenous and
often focal expression of HLA-D products was seen. In one case tumour cells not expressing HLA-DR
antigens were adjacent to strongly HLA-DR expressing non-neoplastic bladder epithelium, indicating a lack of
inducible HLA-DR in the tumour cells. LFA-3 was undetectable in two of 18 cases with the remaining 16
cases showing moderate to strong expression of the molecule. These findings indicate that a substantial
proportion of bladder tumours have one or more of a wide range of different alterations in the expressions of
immunoregulatory molecules that could contribute to escape from immune surveillance.
There has been considerable debate as to whether
immunosurveillance is of relevance in providing protection
against development of malignancy (for review see Oliver,
1985). The recent evidence that use of T cell growth factor,
interleukin-2 can produce long term remission in patients
with renal cell carcinoma and malignant melanoma
(Rosenberg et al., 1987), has led to a rebirth of interest in
this debate, particularly with the demonstration that altera-
tions in tumour major histocompatibility complex (MHC)
expression may be important in determining which patients
respond to treatment (Cohen et al., 1987).
The recognition of neo-antigens by T cells occurs in the
context of MHC molecules which are polymorphic cell sur-
face glycoproteins expressed in two forms: class I (HLA-
A,B,C) and class II (HLA-D). These molecules act as restric-
tion elements for presentation of foreign antigens to mostly
CD8 positive T cytotoxic (CTL) and CD4 positive T helper
cells respectively (Zinkernagal & Doherty, 1979). Individual
HLA allele products, even those mapping to the same locus,
vary in their ability to present different antigen epitopes
(Gotch et al., 1987; McMichael et al., 1986).
Class I antigens are composed of a heavy chain and a light
chain, P2 microglobulin, whose association with the heavy
chain is required for surface expression of class I antigens
(Arce Gomez et al., 1978). An additional factor contributing
to efficiency of CTL activity is the interaction between CD2
molecules on T cells and lymphocyte function-associated
antigen-3 (LFA-3) on target cells in a non-antigen-specific
manner (Krensky et al., 1984).
Evidence that loss of MHC class I antigen on tumours led
to increased malignancy first came from studies of murine
tumours (for review see Festenstein & Schmidt, 1981). Later
studies showed that transfection of the missing MHC class I
gene into these tumour cells led to a reversal of
tumourgenicity or of metastatic potential (Hui et al., 1985;
Wallich et al., 1985) and more importantly, after immunisa-
tion with such altered tumour, exposed mice were resistant to
the original class I deficient tumour (Hui et al., 1985).
Increasingly it is being recognised that loss of class I
antigen expression may be a frequent event in a human
malignancy. Class I antigen loss has been demonstrated in a
substantial proportion of colon adenocarcinomas (Smith et
al., 1988; Rees et al., 1988; Momburg et al., 1986), breast
carcinoma (Fleming et al., 1981) and Burkitt lymphomas
(Masucci et al., 1987) providing a possible mechanism for
escape from immune surveillance.
There has long been interest in the possibility that bladder
cancer may be a tumour where immune surveillance is im-
portant because of a strong association of prognosis with
degree of lymphocyte infiltration, occurrence of spontaneous
regression and the presence of anti-tumour cytotoxic cir-
culating lymphocytes (for review see Oliver, 1985).
In an attempt to assess whether alterations in tumour
expression of immunoregulatory molecules does occur in this
group of tumours, tumour sections from a series of patients
with bladder cancer have been screened with monoclonal
antibodies (Mab) to MHC class I and II antigens and to
LFA-3 molecule.
Materials and methods
Clinical materials
Post-mortem bladder tissue which was microscopically and
histologically normal was sampled from two individuals
within 24 h of death. Operative specimens were also collected
from TCC patients admitted for surgery to the London
Hospital. There were five females with an age range of 50-76
years (mean age of 66 years) and 13 males with an age range
of48-85 years (mean age of 68 years). All but three cases (5,
8 and 10, Table 1) had had surgery at least once before this
tissue sampling. In each case the specimen was divided into
two portions; one was sent for histological examination and
the other was stored in liquid nitrogen until use. Histological
examination of the cases indicated that they were all TCC
with nine of 18 showing no invasion and nine showing
varying degrees of invasion.
Monoclonal antibodies and HLA determinants
The Mabs used as primary reagents in the form of tissue
culture supernatants, are listed as follows together with their
specificities: BBM.1 detects P2m (Brodsky et al., 1979); HC-
10 detects HLA-A,B,C free heavy chain (i.e. not associated
with P2m) with a preference for HLA-B products (Stam et
al., 1986); PA 2.6 and W6/32 detect all P2m-associated HLA-
A,B,C antigens (Brodsky et al., 1979); GAP A3 detects HLA-
A3 (Berger et al., 1982); 116.5.28 detects HLA-Bw6 (K.
Gelsthorpe, unpublished data); TS2/9 detects LFA-3 (Kren-
sky et al., 1983); SPLV3 detects HLA-DQ (Spits et al., 1984);
TU39 detects all HLA-D antigens (Pawelec et al., 1982);
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Table I Expression ofHLA-A,B,C and LFA-3 molecules on bladder tumours
Mature HLA-A,B,C P2-M A2 + B17 A2 + Aw69 A3 Bw4 B26 LFA-3
Patient Cases HLA-A,B,C Heavy chain (BBM.J) (MA2.1) (BB7.2) (GAPA3) (116.5.28) (126.39) (TS2/9)
1 N 4s 4s 4s - - 4s 4s
2 N 4s 4s 4s - - 4s 4s
3 N 4s 4s 4s 4s 4s 4m - 4s 4s
4 I 4s 4m 4s - - - 4m 4m
5 I 4s 4m 4s 4m 4w - 3m 4s
6 N 4s 4m 4s 4s 4w 4m 4w 4m 4s
7 I 4s 0 4s 4m 3w - - 4w 4s
8 I 4s 4w 4s 4s 4s 4w n.d. 4s 4m
9 I 4s 4w 4s 4m 4s 4m
10 N 4m 0 4s 4m 4w - 4w 4m
11 N 4w 0 4w 0 0 0 44w 4m
12 N 4w 4w 4w - - 4w 0 - 4m
13 I 3m 0 4m - - 4w 0 4m
14 N 2s Is 2s - - - 2w Is 4m
15 I 2s Im 3m 3s n.d. - - - 0
16 N lw 0 lw - - - 0 0 4m
17 I lw 0 lw - n.d. - 0 - 4m
18 I 0 0 0 0 0 0 0 0 0
Assessment: no stromal or tumour cell staining= -, stromal staining present but tumour negative = 0, stromal and tumour cell staining
present = grades 1, 2,3 and4. Grade 1 < 10%, grade2> 10% but <50%, grade3 > 50% but <95% andgrade4>95% oftumourcellsstain
positively. The strength ofantigen expression wasgraded as strong = s, moderate = m and weak = w. n.d. = fornotdone, I = invasive tumour
and N = non-invasive tumour.
L243 detects HLA-DR (Lampson & Levy, 1980); B7/21
detects HLA- DP (Watson et al., 1983) and anti-CD3, -CD4
and -CD8 Mabs (Ortho Pharmaceutical) detect total T, T
helper and T cytotoxic lymphocytes subsets respectively.
The immunohistochemical specificity of the Mabs directed
against HLA-A,B,C allele products was demonstrated by
their reactivity on tumour stroma in a series of 12 breast
carcinomas, which has been HLA-typed (Dr J.G. Bodmer,
unpublished data).
Immunohistochemistry
Frozen sections were cut using a cryostat at a thickness of
71m, placed on microscope slides and kept at -80°C until
used. The sections were stained as described by Smith et al.
(1989). The area of tumour sections varied from 9 to 35 mm2.
Selected cases with adequate material had repeat testing to
establish acceptable reproducibility.
Assessment
Immunohistochemical staining on epithelium and stroma was
assessed in normal bladder (where available) and neoplastic
bladder tissues. HLA-A,B,C type was deduced from the reac-
tion of the Mabs directed against polymorphic HLA-A,B,C
determinants with tumour stroma. Expression of antigens on
tumour cells were graded semi-quantitatively by comparison
to the degree of expression on the stromal cells (see Table I).
Results
HLA-A,B,C antigens
Staining of tissue sections from two normal bladders showed
strong positive staining in 100% of epithelial cells with Mab
against class I antigens (W6/32 and PA2.6) and LFA-3 (TS2/
9) and no staining for class II antigens defined by mono-
clonal antibody L243.
The tumour cells of one of 18 cases showed a complete
loss of all HLA-A,B,C molecules (Table I, case 18, Figure 1).
Using Mabs against class I monomorphic determinants, W6/
32 and PA2.6, comparable strength of antigen expression
between all tumour cells and tumour stromal cells was seen
in ten of 18 cases. Of the remaining seven cases, three
showed moderate to strong staining on a proportion of
tumour cells and four showed weak or absent staining on all
cells.
Figure 1 Case no. 18 stained with PA2.6 (monomorphic HLA-
A,B,C). Negative tumour and positive stroma. Tu and st denote
tumour and stroma respectively in this figure and subsequent
figures except Figure 2a.
Although the expression of HLA-A,B,C free heavy chain
(unassociated with P2-microglobulin) as detected by Mab
HC-10 usually mirrored the expression of mature (p2-
microblobulin associated) heavy chain as detected by Mab
PA2.6, in cases 7, 10 and 13 free heavy chain was undetec-
table despite moderate to strong expression of mature heavy
chain (Table I).
Of greater interest was the observation that there were
patients whose tumour showed selective loss of some class I
antigens. Selective loss was defined as complete absence of a
specific HLA-A,B or C product from tumour cells in the
presence of moderate to strong expression of monomorphic
HLA antigens on tumour stroma. Because ofuniformly weak
or absent expression of all HLA-A and B antigens detected
by monomorphic determinants, five of 18 cases could not be
scored for selective loss. One of the remaining 13 tumours
showed unequivocal selective loss confirmed by retesting on
three separate occasions. This was one of the 12 tumours
whose stroma was positive for Bw6. None of seven A-2
positive none of four A-3 positive and none of three Bw4
positive tumours showed selective loss (Table I, Figure 2a,b).
Partial degrees of selective HLA-A,B,C allele product loss
are difficult to identify with certainty, though cases showing
strong staining with monomorphic HLA-A,B,C Mabs but
weak staining with some polymorphic Mabs (such as case 7)
which demonstrate weak expression of Bw6 but strong ex-
pression of A-2 may be examples of this phenomenon. UsingHLA-A,B,C AND LFA-3 IN BLADDER CANCER 605
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Figure 2 a, Case no. 13 stained with W6/32 (monomorphic
HLA-A,B,C). Positive tumours and positive stroma. b, Case
no. 13 stained with 126.39 (anti HLA-Bw6). Negative tumour and
positive stroma.
Figure 3 Case no. 11 staining with HB55 (anti HLA-DR).
Negative tumour and positive stroma.
Figure 4 Case no. 15 staining with TS 2/9 (anti LFA-3).
Negative tumour and limited staining of stroma.
this lower definition of loss, only four of 18 could be said to
have totally normal expression of HLA-A,B,C with the
available Mabs against monomorphic and polymorphic
determinants.
The pattern of antigen expression on tumour cells using
Mabs specific for class II antigens was heterogeneous and
often focal. Although nine of nine were positive for the 'core'
HLA-D antigen recognised by Mab TU39. Seven of nine
were positive for DR, five of nine positive for DQ and three
of nine positive for DP. HLA-DP and DQ expression mir-
rorea HLA-DR and in no case was a tumour observed to be
HLA-DR negative yet HLA-DP or DQ positive. There was
not any direct correlation between the expression of HLA-D
h antigens and that of degree of T cell infiltration (see below)
into the tumour area. In one case (11) strong expression of
HLA-DR antigen was observed on normal epithelium adja-
cent to HLA-DR negative neoplastic epithelium (Figure 3).
LFA-3 was expressed with moderate to strong intensity in
16 of 18 cases. There were two cases of complete LFA-3 loss
(cases 15, 18, Table I, Figure 4) and in both cases the
HLA-A,B,C antigens were either lost or down-regulated.
In a subset of the cases, the nature of tumour infiltrating
lymphocytes was investigated using Mabs specific for
A different T cell subtypes. T cells (CD4>>CD8) positive
were found to be present in tumour stroma (11 of 12 cases)
the intra-epithelially (eight of 12).
Discussion
Although post-mortem material is not ideal for such studies
because of risk of autolysis and problems of induction of
class II antigen by terminal bladder infection, the results do
confirm the observations from larger studies (Gardiner et al.,
1985) that class I but not class II is expressed on normal
usothelium.
Against this background the results of these tumour
studies have demonstrated that HLA-A,B,C antigen expres-
t sion is demonstrated in over a third ofTCCs. Also, there was
a definite case (13) of selective loss of HLA-Bw6 antigen in
the presence of normal expression of other HLA-A,B,C pro-
ducts, two cases of complete loss of LFA-3 molecules (both
of which also had either complete or partial loss of all class I
antigens) and, finally, a single example where HLA-D
antigen expression was observed on normal epithelium adja-
cent to negative neoplastic epithelium. All of these abnor-
malities in the expression of a immunoregulatory molecules
could be capable of conferring a selective growth advantage
to tumour cells by enabling escape from T cell immune
attack directed against tumour specific antigens.
The selective loss of HLA-A,B,C allele products from
neoplastic cells has previously been reported in other tumour
types. These include Burkitt lymphoma (Masucci et al., 1987)
and colorectal adenocarcinoma (Smith et al., 1989; Rees et
al., 1988; Momburg et al., 1989). Such a selective loss ofclass
I antigens could confer resistance to immune attacks against
tumour, given the varying ability of different HLA-A,B,C
allele products to present antigen epitopes to cytotoxic T
cells. Thus, the loss of a single allele product could be
functionally equivalent, in terms ofescape from T cell attack,
to the loss of all HLA-A,B,C molecules. Selective losses of
HLA-A,B,C allele products could result from a single genetic
mutation, whereas loss of all HLA-A,B,C antigens (e.g. case
P 18) would usually require more than a single mutation.
The incidence of colorectal adenocarcinomas with abnor-
mal HLA-A,B,C antigen expression (11 of 30 cases) (Smith et
al., 1989) was similar to that reported in this study ofbladder
g tumours. However, in contrast to the situation demon-
stratable in the bladder, most HLA-A,B,C loss in colorectal
carcinomas was of individual HLA-A,B,C allele products and
not a generalised loss of all HLA-A,B,C antigens as in
bladder where there was an unexpectedly high frequency of
loss of free heavy chain. This deserves further investigation.
The absence of detectable HLA-A,B,C free heavy chain in
tumours expressing mature HLA-A,B,C antigen was seen in606 A.M.E. NOURI et al.
three cases (7, 10 and 13). The basis of this interesting
observation may be a slow rate of HLA-A,B,C antigen
synthesis by tumour cells.
Class II antigen expression as detected by TU39 Mab was
often focal and of variable intensity on tumour cells of all
nine case studies. Locus product specific Mabs for DR, DP
and DQ also showed patch areas of positivity on the tumour
cells. Similar results regarding the expression of class II
antigens on neoplastic bladder epithelium were also reported
by Gardiner et al. (1985).
The significance of class II antigen expression on bladder
tumour cells is not clear, but it is conceivable that the
detection of tumour antigen by infiltrating T cells results in
the production ofcytokines which in turn stimulate induction
of tumour class II products. The presence of T cells in both
tumour stroma and intra-epithelial areas is agreement with
this hypothesis. Supportive evidence comes also from the
observation that it has been possible to use interleukin-2
(IL-2) to expand activated T cells from six of 18 of these
tumour biopsies using 11-2 after culture of tumour cell
suspension (A. Nouri, in preparation).
The complete loss of LFA-3 molecules from tumour cells
occurred in two of 18 cases. This may give tumour additional
advantage to escape from immune surveillance given the
importance of LFA-3 binding to CD2 molecules on CD8
cytotoxic cells to initate cytoxicity. The fact that LFA-3 loss
is not, however, confined to bladder neoplasia, having been
also demonstrated in colorectal adenocarcinoma (Smith et
al., 1989) and Burkitt lymphoma (Gregory et al., 198P.)
would also support this observation. It is interesting to note
that the two cases (15 and 18) showing LFA-3 losses also
showed complete or major down-regulation of HLA-A,B,C
antigens.
Given the focal nature ofthese antigen losses and the small
size of tumour sample tested, it is obvious that the frequency
of loss reported in this study is a minimum incidence.
Attempts were made to correlate the presence or absence
of invasion (according to UICC system) with class I antigen
expression on tumour cells. No significant association was
demonstrated in the small numbers tested but it is of interest
that the tumour not expressing any HLA-A,B,C antigen or
LFA-3 (case 18), a further tumour not expressing LFA-3
(case 14) and the tumour showing the loss of HLA-Bw6 (case
13) were all invasive and no non-invasive tumour showed this
degree of loss. More extensive testing is required to clarify
whether loss of these immuno-regulatory molecules does lead
to selective growth advantage to tumour.
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